A New York-based real estate investment company has finished its $47 million acquisition of Specialty Laboratories Inc.’s Santa Clarita headquarters.
Lexington Corporate Properties Trust purchased Specialty Laboratories’ newly-constructed three-story 187,262-square-foot office, research and development and laboratory facility on 13.8 acres on Tourney Road in sale and leaseback transactions.
Under the terms of the sale, Specialty Laboratories will lease the property for 20 years. Lexington and Specialty Laboratories have been working on the sale since February.
Lexington is a real estate investment trust that owns and manages office, industrial and retail properties that are leased to various companies throughout the United States. The firm also provides investment advisory and asset management services to investors in the net lease area.
Specialty Laboratories is a clinical laboratory for more than 10,000 hospitals and physicians in the United States.
Currently Specialty Laboratories operations are divided among four separate buildings in Santa Monica. The company said its new facility in Santa Clarita will allow it to consolidate its operations into a single building and increase its available space for future growth and capacity.
Specialty Laboratories began moving into its office, research and development and laboratory facility over the summer. The company anticipates the move will be complete in early 2005.
“We believe our new headquarters and laboratory facility ... will enable us to enhance our laboratory services platform and increase our long-term growth opportunities,” Specialty Laboratories CEO Douglas S. Harrington said in a statement in July.
“Having already completed a complex restructuring of our laboratory operations, reasserted a competitive presence in the laboratory services marketplace and achieved top-line growth over several quarters, Specialty is in an excellent position to take advantage of the operating efficiencies and other potential benefits afforded by our new facility.
“Although the costs associated with the relocation and new facility will likely postpone the achievement of short-term profitability, we believe the long-term benefit to our operations and our clients will be substantial,” he said.
Shares of Specialty Laboratories fell 16 cents, or 1.46 percent, to $10.83 on the New York Stock Exchange on Wednesday.
